

The Board of Director's statement pursuant to Chapter 19, Section 22 of the Swedish Companies Act

The Board of Directors of Egetis Therapeutics AB (publ) ("**Egetis**") has proposed that the annual general meeting on May 6, 2024 resolves to authorize the Board of Directors to acquire a total of 29,000,000 class C shares in Egetis. The Board of Directors considers, in view of what is stated below, that the resolution to acquire own class C shares is justifiable with respect to the requirements that the business' nature, scale and risk place on the amount of equity, as well as the need for Egetis to strengthen the balance sheet, liquidity and position as a whole. The Board of Directors has also taken into account the requirements of the group's business, scope and risk place on the group's equity requirement and need for the group to strengthen its balance sheet, liquidity and position as a whole.

Equity

The Board of Directors considers that the equity of Egetis will be of sufficient amount after the proposed acquisitions. The Board of Directors has hereby taken into account the business, scope and the risks that the business is associated with and the current economic situation, historical development and forecasts for Egetis as well as for the market.

Need of strengthening of the balance sheet, liquidity and position as a whole

The Board of Directors has made a comprehensive assessment of Egetis' financial position and its ability to, in the long term, fulfil its undertakings. As stated in Egetis' annual report for 2023, the unrestricted equity in the parent company of the group was SEK 521.7 million as per December 31, 2023.

The proposed acquisitions do not affect Egetis' ability to in due time fulfil its present and anticipated financial obligations or Egetis' ability to implement planned investments.

The Board of Directors has also considered other known matters that may affect Egetis' financial position and that have not been considered within the scope of the above mentioned. No other matter that would make the proposed acquisitions unjustifiable has been identified during such analysis.

Stockholm in April 2024

Egetis Therapeutics AB (publ)

The Board of Directors